PE20221443A1 - Composiciones y metodos para el tratamiento de infecciones virales - Google Patents

Composiciones y metodos para el tratamiento de infecciones virales

Info

Publication number
PE20221443A1
PE20221443A1 PE2022000373A PE2022000373A PE20221443A1 PE 20221443 A1 PE20221443 A1 PE 20221443A1 PE 2022000373 A PE2022000373 A PE 2022000373A PE 2022000373 A PE2022000373 A PE 2022000373A PE 20221443 A1 PE20221443 A1 PE 20221443A1
Authority
PE
Peru
Prior art keywords
treatment
viral infections
compositions
methods
conjugates
Prior art date
Application number
PE2022000373A
Other languages
English (en)
Inventor
James M Balkovec
Daniel C Bensen
Allen Borchardt
Thomas P Brady
Zhi-yong CHEN
Jason Cole
Quyen-Quyen Thuy Do
Simon Doehrmann
Wanlong Jiang
Thanh Lam
Alain Noncovich
Leslie W Tari
Original Assignee
Cidara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics Inc filed Critical Cidara Therapeutics Inc
Publication of PE20221443A1 publication Critical patent/PE20221443A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

La presente invencion se refiere a las composiciones y metodos para el tratamiento de infecciones virales, los cuales incluyen conjugados que contienen inhibidores de neuraminidasa viral como zanamivir, peramivir o analogos de estos, unidos estructuralmente a E, que comprende un monomero de dominio Fc, un dominio Fc, un peptido de union a Fc, una proteina albumina o peptido de union de albumina. Asimismo, la estructura de los conjugados tambien presenta los radicales A1 y A2, que se seleccionan independientemente de cualquiera de las formulas (A-I) y (A-XII) descritas en la presente; al enlazador L, que se acopla a A1 y A2 y se une covalentemente a E o a un atomo de nitrogeno de una lisina o azufre que forman parte de las proteinas de E; y donde T es un numero entero de 1 a 20. Generalmente, los conjugados se pueden administrar para el tratamiento de infecciones virales provocadas por el virus de la influenza o parainfluenza.
PE2022000373A 2019-09-06 2020-09-08 Composiciones y metodos para el tratamiento de infecciones virales PE20221443A1 (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962897036P 2019-09-06 2019-09-06
US201962941405P 2019-11-27 2019-11-27
US201962948143P 2019-12-13 2019-12-13
US202062959857P 2020-01-10 2020-01-10
US202062966500P 2020-01-27 2020-01-27
US202062970491P 2020-02-05 2020-02-05
US202062984705P 2020-03-03 2020-03-03
US202062988304P 2020-03-11 2020-03-11
US202063032488P 2020-05-29 2020-05-29
US202063062377P 2020-08-06 2020-08-06
PCT/US2020/049772 WO2021046549A1 (en) 2019-09-06 2020-09-08 Compositions and methods for the treatment of viral infections

Publications (1)

Publication Number Publication Date
PE20221443A1 true PE20221443A1 (es) 2022-09-21

Family

ID=74852729

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000373A PE20221443A1 (es) 2019-09-06 2020-09-08 Composiciones y metodos para el tratamiento de infecciones virales

Country Status (18)

Country Link
US (3) US20210220478A1 (es)
EP (1) EP4025256A4 (es)
JP (1) JP2022546609A (es)
KR (1) KR20220088527A (es)
CN (1) CN114980933A (es)
AU (1) AU2020342649A1 (es)
BR (1) BR112022004058A2 (es)
CA (1) CA3153359A1 (es)
CL (1) CL2022000531A1 (es)
CO (1) CO2022003078A2 (es)
CR (1) CR20220138A (es)
EC (1) ECSP22026797A (es)
IL (1) IL290792A (es)
MX (1) MX2022002728A (es)
PE (1) PE20221443A1 (es)
TW (1) TW202122117A (es)
WO (1) WO2021046549A1 (es)
ZA (1) ZA202203681B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210166A (es) 2018-09-06 2021-07-27 Cidara Therapeutics Inc Composiciones y métodos para el tratamiento de infecciones virales
US20240024497A1 (en) 2020-08-06 2024-01-25 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
US20230364251A1 (en) 2020-08-06 2023-11-16 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
CA3211494A1 (en) 2021-03-11 2022-09-15 Leslie W. Tari Protein-drug conjugates for antiviral therapy
WO2023125806A1 (zh) * 2021-12-30 2023-07-06 苏州爱科百发生物医药技术有限公司 用于预防和治疗病毒感染的偶联物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2271249C (en) 1996-11-14 2010-07-20 Biota Scientific Management Pty. Ltd. Macromolecular neuraminidase-binding compounds
AUPP913999A0 (en) 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879701A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
CA2835489C (en) 2010-05-10 2018-03-06 Chi-Huey Wong Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TR201809571T4 (tr) 2013-03-15 2018-07-23 Hoffmann La Roche Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
WO2017046625A1 (en) 2015-06-25 2017-03-23 Cube Biotech Gmbh New chelators for affinity purification of recombinant proteins
US20230190950A1 (en) * 2017-01-06 2023-06-22 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
CR20210166A (es) * 2018-09-06 2021-07-27 Cidara Therapeutics Inc Composiciones y métodos para el tratamiento de infecciones virales

Also Published As

Publication number Publication date
WO2021046549A1 (en) 2021-03-11
CO2022003078A2 (es) 2022-07-08
CL2022000531A1 (es) 2022-10-28
CA3153359A1 (en) 2021-03-11
KR20220088527A (ko) 2022-06-27
CR20220138A (es) 2022-07-28
ECSP22026797A (es) 2022-05-31
EP4025256A4 (en) 2023-12-13
US20210220478A1 (en) 2021-07-22
IL290792A (en) 2022-04-01
ZA202203681B (en) 2023-11-29
EP4025256A1 (en) 2022-07-13
WO2021046549A8 (en) 2021-05-20
US20230398226A1 (en) 2023-12-14
CN114980933A (zh) 2022-08-30
BR112022004058A2 (pt) 2022-05-31
TW202122117A (zh) 2021-06-16
JP2022546609A (ja) 2022-11-04
MX2022002728A (es) 2022-08-04
AU2020342649A1 (en) 2022-03-24
US11510992B1 (en) 2022-11-29

Similar Documents

Publication Publication Date Title
PE20221443A1 (es) Composiciones y metodos para el tratamiento de infecciones virales
PH12021550822A1 (en) Compositions and methods for the treatment of viral infections
CO2019008531A2 (es) Análogos de atazanavir (atv) para tratar infecciones por vih.
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CO2018009533A2 (es) Conjugados de amanitina
EA201992784A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201900025A1 (ru) Противовирусное иммунотропное средство для лечения орви
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
EA201992782A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201991065A1 (ru) Вакцина против свиного парвовируса
BR112019004189A2 (pt) trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos
Hoffmann et al. A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment
EA202091012A1 (ru) Композиции фосфорилированных тау-пептидов и их применения
CO2022000029A2 (es) Preparados de prevotella y tratamiento de la enfermedad pulmonar obstructiva crónica (epoc) y otras afecciones pulmonares
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
CY1124943T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν rpl554 σε hfa-134a για χορηγηση με εισπνοη
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
BR112022024149A2 (pt) Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno
AR117652A1 (es) Composiciones farmacéuticas que comprenden conjugados de anticuerpo anti-191p4d12 y fármaco y métodos de usarlas
BR112021024788A2 (pt) Conjugados de variante de receptor de complemento solúvel tipo 1 e usos dos mesmos
CO2023000239A2 (es) Excipientes reductores de viscosidad y combinaciones de los mismos para formulaciones de proteína altamente concentradas
CL2022001545A1 (es) Composiciones y métodos para tratar y prevenir la influenza
WO2014160171A3 (en) Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
BR112019024796A2 (pt) Peptídeos e usos dos mesmos como agentes antivirais
BR112022022263A2 (pt) Tratamento de infecções virais